Disease or Syndrome – Page 68

Major Clinical Trial Failures of 2024: Setbacks in Neuroscience and Beyond

9 months ago talkbio0Tagged Alzheimer 's disease, Amyotrophic Lateral Sclerosis, Clinical Trials, Drug Development, Duchenne, Neoplasms, Neuroscience discipline, Schizophrenia

Clinical trials, drug development, neuroscience, ALS, Alzheimer’s disease, schizophrenia, Duchenne muscular dystrophy, oncology

Gilead’s Seladelpar Receives Conditional EU Approval for Primary Biliary Cholangitis Treatment

9 months ago talkbio0Tagged Biliary Cholangitis, Commission, Conditional, European (ethnic group), Gilead Sciences, Primary Biliary Cholangitis, Response process, seladelpar, ursodiol

Seladelpar, Gilead Sciences, primary biliary cholangitis, PBC, European Commission, conditional marketing authorization, RESPONSE trial, ursodeoxycholic acid (UDCA)

HOOKIPA Pharma Terminates Acquisition Talks with Poolbeg Pharma

9 months ago talkbio0Tagged acquisition termination, biotech merger, HOOKIPA, immunotherapeutics, Pharma, Poolbeg

biotech merger, acquisition termination, HOOKIPA Pharma, Poolbeg Pharma, immunotherapeutics, rare disease

Biotech M&A Heats Up: Cosette’s $430M Mayne Pharma Acquisition and Industry-Wide Stock Buybacks

9 months ago talkbio0Tagged Acquisitions, biotech, Dermatology field, Lung consolidation, Market, pharmaceutical mergers, stock repurchase programs, women 's health

Biotech acquisitions, pharmaceutical mergers, stock repurchase programs, women’s health, dermatology, market consolidation

BridgeBio’s Attruby Gains FDA Approval, Challenging Pfizer’s Tafamidis in ATTR-CM Treatment

9 months ago talkbio0Tagged Acoramidis, Approved, ATTR-CM, Attruby, BridgeBio, Cardiomyopathies, Pfizer, Prealbumin, Stabilizer - function, tafamidis, United States Food and Drug Administration

Attruby, acoramidis, BridgeBio, ATTR-CM, tafamidis, Pfizer, FDA approval, transthyretin stabilizer, cardiomyopathy

AstraZeneca Acquires FibroGen’s China Unit for $160 Million, Gaining Full Control of Anemia Drug Roxadustat

9 months ago talkbio0Tagged Acquisition, Anemia, AstraZeneca, China, Chronic Kidney Diseases, Drug Industry, FibroGen, roxadustat

AstraZeneca, FibroGen, China, acquisition, roxadustat, anemia, chronic kidney disease, pharmaceutical industry

Trump’s Healthcare Nominees Pledge to Divest Industry Investments Amid Controversy

9 months ago talkbio0Tagged Bhattacharya, healthcare appointments, Industry, Jay, Jr., Mehmet, Myasthenic Syndromes, Congenital, NIH, NIH Mouse, ounce, ties, Transplant Registry Unified Management Program

Trump administration, healthcare appointments, NIH, CMS, divestment, industry ties, Jay Bhattacharya, Mehmet Oz, Robert F. Kennedy Jr.

Illumina Announces Layoffs as Incyte Forges AI Partnership for Drug Discovery

9 months ago talkbio0Tagged Artificial Intelligence, Drug Discovery, FOXD3 gene, Gemini of Coiled Bodies, Illumina, Incyte, Partnership

Illumina, layoffs, Incyte, Genesis Therapeutics, AI partnership, drug discovery, GEMS platform, small molecule therapeutics

Ascletis Advances in Obesity Treatment with Promising Oral GLP-1 Data

9 months ago talkbio0Tagged ASC30, Ascletis, Chinese Language, Glucagon-Like Peptide 1, Obesity, Oral cavity, Pharma, pharmaceutical innovation

Ascletis Pharma, oral GLP-1, obesity treatment, weight loss, ASC30, Chinese biotech, pharmaceutical innovation

Cabaletta’s CABA-201 CAR-T Therapy Shows Promising Results in Lupus and Other Autoimmune Diseases

9 months ago talkbio0Tagged Autoimmune Diseases, B-Lymphocytes, CABA-201, CAR-T, Clinical Trials, Lupus Vulgaris

CABA-201, CAR-T therapy, lupus, autoimmune diseases, clinical trials, remission, B cell depletion